Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Minority Interest (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Minority Interest data on record, last reported at -$1.2 million in Q4 2025.

  • For Q4 2025, Minority Interest rose 12.13% year-over-year to -$1.2 million; the TTM value through Dec 2025 reached -$1.2 million, up 12.13%, while the annual FY2025 figure was -$1.2 million, 12.13% up from the prior year.
  • Minority Interest reached -$1.2 million in Q4 2025 per LCTX's latest filing, up from -$1.2 million in the prior quarter.
  • Across five years, Minority Interest topped out at -$1.1 million in Q1 2021 and bottomed at -$1.5 million in Q3 2023.
  • Average Minority Interest over 5 years is -$1.3 million, with a median of -$1.4 million recorded in 2025.
  • Peak YoY movement for Minority Interest: skyrocketed 36.59% in 2021, then decreased 24.22% in 2022.
  • A 5-year view of Minority Interest shows it stood at -$1.1 million in 2021, then decreased by 24.93% to -$1.4 million in 2022, then rose by 0.5% to -$1.4 million in 2023, then increased by 1.93% to -$1.4 million in 2024, then grew by 12.13% to -$1.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Minority Interest were -$1.2 million in Q4 2025, -$1.2 million in Q3 2025, and -$1.3 million in Q2 2025.